{"DataElement":{"publicId":"7241723","version":"1","preferredName":"WHO 2016 Classification Primary Brain Tumor Code","preferredDefinition":"WHO 2016 Classification codes for primary brain tumors.","longName":"WHO2016_PRI_BRTMR_CD","context":"ABTC","contextVersion":"1","DataElementConcept":{"publicId":"7241619","version":"1","preferredName":"WHO Classification of Tumors Primary Brain Neoplasm","preferredDefinition":"A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings._Occurring first in time or sequence; original; of greatest rank or importance or value._A benign or malignant neoplasm that arises from or metastasizes to the brain.","longName":"5210896v1.0:7241722v1.0","context":"ABTC","contextVersion":"1","ObjectClass":{"publicId":"5210896","version":"1","preferredName":"WHO Classification of Tumors","preferredDefinition":"A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings.","longName":"C113304","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Classification of Tumors","conceptCode":"C113304","definition":"A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FC19F3A-FB6B-BEEA-E050-BB89AD436723","latestVersionIndicator":"Yes","beginDate":"2016-04-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-04-05","modifiedBy":"ONEDATA","dateModified":"2016-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7241722","version":"1","preferredName":"Primary Brain Neoplasm","preferredDefinition":"Occurring first in time or sequence; original; of greatest rank or importance or value.:A benign or malignant neoplasm that arises from or metastasizes to the brain.","longName":"C25251:C2907","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary","conceptCode":"C25251","definition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Brain Neoplasm","conceptCode":"C2907","definition":"A benign or malignant neoplasm that arises from or metastasizes to the brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2CAB875-5163-0E0F-E053-F662850A69C6","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-08","modifiedBy":"ONEDATA","dateModified":"2020-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2BB5838-FC60-7FE6-E053-F662850A33BE","latestVersionIndicator":"Yes","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"TSESU","dateModified":"2022-07-06","changeDescription":"Created for ABTC 1802 study in Rave. smt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7241719","version":"1","preferredName":"WHO 2016 Primary Brain Tumors Code","preferredDefinition":"A symbol or combination of symbols which is assigned to the members of a collection.","longName":"7241719v1.0","context":"ABTC","contextVersion":"1","type":"Enumerated","dataType":"ALPHANUMERIC","minLength":null,"maxLength":"65","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"9400/3","valueDescription":"Diffuse astrocytoma","ValueMeaning":{"publicId":"2578704","version":"1","preferredName":"Diffuse astrocytoma","longName":"2578704","preferredDefinition":"A low-grade (WHO grade II) astrocytic neoplasm. It is characterized by diffuse infiltration of neighboring central nervous system structures. These lesions typically affect young adults and have a tendency for progression to anaplastic astrocytoma and glioblastoma. Based on the IDH genes mutation status, diffuse astrocytomas are classified as IDH-mutant, IDH-wildtype, and not otherwise specified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Astrocytoma","conceptCode":"C7173","definition":"A low-grade (WHO grade 2) astrocytic neoplasm. It is characterized by diffuse infiltration of neighboring central nervous system structures. These lesions typically affect young adults and have a tendency for progression to anaplastic astrocytoma and glioblastoma. Based on the IDH genes mutation status, diffuse astrocytomas are classified as IDH-mutant, IDH-wildtype, and not otherwise specified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-007D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-10","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2004-03-10","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D5EE-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9538/3","valueDescription":"Papillary Meningioma","ValueMeaning":{"publicId":"2838615","version":"1","preferredName":"Papillary Meningioma","longName":"2838615","preferredDefinition":"A rare WHO grade III meningioma defined by the presence of a perivascular pseudopapillary pattern in at least part of the tumor. They are clinically aggressive. (Adapted from WHO 2000.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Meningioma","conceptCode":"C3904","definition":"A WHO grade III meningioma characterized by the predominance of a perivascular pseudopapillary pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AFE7-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D602-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9411/3","valueDescription":"Gemistocytic Astrocytoma, IDH-Mutant","ValueMeaning":{"publicId":"5698566","version":"1","preferredName":"Gemistocytic Astrocytoma, IDH-Mutant","longName":"5698566","preferredDefinition":"Gemistocytic astrocytoma carrying IDH mutations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemistocytic Astrocytoma, IDH-Mutant","conceptCode":"C129272","definition":"Gemistocytic astrocytoma carrying IDH mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B2D3-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D60C-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9441/3","valueDescription":"Giant Cell Glioblastoma","ValueMeaning":{"publicId":"2578703","version":"1","preferredName":"Giant Cell Glioblastoma","longName":"2578703","preferredDefinition":"A rare histological variant of Glioblastoma (WHO grade IV) with a predominance of bizarre, multinucleated giant cells, an occasionally abundant stromal reticulin network and a high frequency of TP53 mutations. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Giant Cell Glioblastoma","conceptCode":"C4325","definition":"A rare histological variant of glioblastoma with a predominance of bizarre, multinucleated giant cells, an occasionally abundant stromal reticulin network, and a high frequency of TP53 mutations. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-007C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"ONEDATA","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D616-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9442/3","valueDescription":"Gliosarcoma","ValueMeaning":{"publicId":"2578705","version":"1","preferredName":"Gliosarcoma","longName":"2578705","preferredDefinition":"A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gliosarcoma","conceptCode":"C3796","definition":"A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-007E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D620-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9445/3","valueDescription":"Glioblastoma, IDH-Mutant","ValueMeaning":{"publicId":"7241617","version":"1","preferredName":"Glioblastoma, IDH-Mutant","longName":"7241617","preferredDefinition":"A glioblastoma associated with IDH1 or IDH2 gene mutations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Astrocytoma, IDH-Mutant, Grade 4","conceptCode":"C167335","definition":"IDH-mutant astrocytoma characterized by the presence of necrosis and/or microvascular proliferation or homozygous deletion of CDKN2A and/or CDKN2B genes. The term glioblastoma no longer applies to central nervous system WHO grade 4 IDH-mutant astrocytomas. (WHO 2021)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2BB4942-215A-7BF9-E053-F662850A0FD0","latestVersionIndicator":"Yes","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"ONEDATA","dateModified":"2020-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D634-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9450/3","valueDescription":"Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted Or Oligodendroglioma, Not Otherwise Specified","ValueMeaning":{"publicId":"7241720","version":"1","preferredName":"Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted Or Oligodendroglioma, Not Otherwise Specified","longName":"7241720","preferredDefinition":"An oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: An oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted","conceptCode":"C129318","definition":"An oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Oligodendroglioma, Not Otherwise Specified","conceptCode":"C129319","definition":"A central nervous system tumor with morphological features of oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2CA80DF-39CC-1138-E053-F662850AD7CE","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-08","modifiedBy":"ONEDATA","dateModified":"2020-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D648-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9401/3","valueDescription":"Anaplastic astrocytoma","ValueMeaning":{"publicId":"2572930","version":"1","preferredName":"Anaplastic astrocytoma","longName":"2572930","preferredDefinition":"A diffusely infiltrating, WHO grade III astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Astrocytoma","conceptCode":"C9477","definition":"A diffusely infiltrating, WHO grade 3 astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E9EF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D652-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9440/3","valueDescription":"Glioblastoma","ValueMeaning":{"publicId":"3686274","version":"1","preferredName":"Glioblastoma","longName":"3686274","preferredDefinition":"The most malignant astrocytic tumor (WHO grade IV). It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Two histologic variants are recognized: giant cell glioblastoma and gliosarcoma. (WHO) ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5C534CC-6FFB-BB02-E040-BB89AD4314F2","latestVersionIndicator":"Yes","beginDate":"2013-02-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D65C-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9451/3","valueDescription":"Anaplastic Oligodendroglioma, Not Otherwise Specified","ValueMeaning":{"publicId":"5698578","version":"1","preferredName":"Anaplastic Oligodendroglioma, Not Otherwise Specified","longName":"5698578","preferredDefinition":"An anaplastic oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Oligodendroglioma, Not Otherwise Specified","conceptCode":"C129322","definition":"A central nervous system tumor with morphological features of anaplastic oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D2B82-B3B7-2EE0-E053-F662850A413A","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D670-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9382/3","valueDescription":"Oligoastrocytoma","ValueMeaning":{"publicId":"2568645","version":"1","preferredName":"Oligoastrocytoma","longName":"2568645","preferredDefinition":"A WHO grade II tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligoastrocytoma","conceptCode":"C4050","definition":"A WHO grade 2 tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-10","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2004-03-10","modifiedBy":"COOPERM","dateModified":"2012-11-09","changeDescription":"Associated concept to VM for TCGA. mc 11/9/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D684-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9424/3","valueDescription":"Pleomorphic Xanthoastrocytoma Or Anaplastic Pleomorphic Xanthoastrocytoma","ValueMeaning":{"publicId":"7241721","version":"1","preferredName":"Pleomorphic Xanthoastrocytoma Or Anaplastic Pleomorphic Xanthoastrocytoma","longName":"7241721","preferredDefinition":"A WHO grade ll astrocytic tumor with a relatively favorable prognosis.  It is characterized by pleomorphic and lipidized cells expressing GFAP often surrounded by a reticulin network and eosinophilic granular bodies. It presents in the superficial cerebral hemispheres and involves the meninges. It typically affects children and young adults.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A WHO grade III pleomorphic xanthoastrocytoma characterized by the presence of five or more mitoses per 10 high-power fields. Necrosis may be present. Patients have shorter survival rates when compared to those with WHO grade II pleomorphic xanthoastrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleomorphic Xanthoastrocytoma","conceptCode":"C4323","definition":"A WHO grade 2 astrocytic tumor with a relatively favorable prognosis.  It is characterized by pleomorphic and lipidized cells expressing GFAP often surrounded by a reticulin network and eosinophilic granular bodies. It presents in the superficial cerebral hemispheres and involves the meninges. It typically affects children and young adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Anaplastic Pleomorphic Xanthoastrocytoma","conceptCode":"C129327","definition":"A WHO grade 3 pleomorphic xanthoastrocytoma characterized by the presence of five or more mitoses per 10 high-power fields. Necrosis may be present. Patients have shorter survival rates when compared to those with WHO grade 2 pleomorphic xanthoastrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2CA80DF-3ADB-1138-E053-F662850AD7CE","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-08","modifiedBy":"ONEDATA","dateModified":"2020-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D698-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9392/3","valueDescription":"Anaplastic Ependymoma","ValueMeaning":{"publicId":"3249041","version":"1","preferredName":"Anaplastic Ependymoma","longName":"3249041","preferredDefinition":"Anaplastic Ependymoma (WHO grade III) is a malignant glioma of ependymal origin with accelerated growth and an unfavorable clinical outcome, particularly in children. Anaplastic Ependymomas show high mitotic activity, often accompanied by microvascular proliferation and pseudo-palisading necrosis. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Ependymoma","conceptCode":"C4049","definition":"A WHO grade 3 malignant glioma of ependymal origin with accelerated growth and an unfavorable clinical outcome, particularly in children. It is characterized by high mitotic activity, often accompanied by microvascular proliferation and pseudo-palisading necrosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CA5E9E-175E-D7DA-E040-BB89AD432E47","latestVersionIndicator":"Yes","beginDate":"2011-06-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D6AC-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9505/3","valueDescription":"Anaplastic Ganglioglioma","ValueMeaning":{"publicId":"3249588","version":"1","preferredName":"Anaplastic Ganglioglioma","longName":"3249588","preferredDefinition":"Anaplastic Ganglioglioma (WHO grade III) is a neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and anaplastic glial cells. These anaplastic changes in the glial component and high MIB-1 and TP53 labelling indices may indicate aggressive behavior.  However, the correlation of histological anaplasia with clinical outcome is inconsistent. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Ganglioglioma","conceptCode":"C4717","definition":"A WHO grade III neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and anaplastic glial cells. The anaplastic changes in the glial component and high MIB-1 and TP53 labeling indices may indicate aggressive behavior. However, the correlation of histological anaplasia with clinical outcome is inconsistent. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D99025-BF36-DBB4-E040-BB89AD434418","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D6C0-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"},{"value":"9530/3","valueDescription":"Anaplastic (Malignant) Meningioma","ValueMeaning":{"publicId":"5043585","version":"1","preferredName":"Anaplastic (Malignant) Meningioma","longName":"5043585","preferredDefinition":"A WHO grade III meningioma characterized by the presence of malignant morphologic features, including malignant cytology and a very high mitotic index (20 or more mitoses per ten high power fields).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic (Malignant) Meningioma","conceptCode":"C4051","definition":"A WHO grade III meningioma characterized by the presence of malignant morphologic features, including malignant cytology and a very high mitotic index (20 or more mitoses per ten high power fields).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24332DE1-107A-F0BF-E050-BB89AD4319C0","latestVersionIndicator":"Yes","beginDate":"2015-11-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3D4249C-D6D4-247A-E053-F662850AF65C","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-21","modifiedBy":"ONEDATA","dateModified":"2020-04-21","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261841","version":"1","preferredName":"Code","preferredDefinition":"A system of numbered categories for representation of data.","longName":"C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FBB87F7A-6427-1AFC-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-13","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-07-13","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2CA80DF-39B2-1138-E053-F662850AD7CE","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-08","modifiedBy":"TSESU","dateModified":"2022-06-24","changeDescription":"Created for ABTC-1802 per N. Danda - smt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280696","version":"1","longName":"Baseline Evaluations","context":"ABTC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"WHO Classification Code for P","type":"Preferred Question Text","description":"WHO Classification Code for Primary Brain Tumors","url":null,"context":"ABTC"}],"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2C7FE67-23CA-0E02-E053-F662850A6AC7","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-08","modifiedBy":"TSESU","dateModified":"2022-07-07","changeDescription":"Created for ABTC 1802 - smt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}